Document is current
Any future updates will be listed below
-
Authors
Fadila, Saja
Krivoshein, Georgii https://orcid.org/0000-0003-4737-5099
Majadly, Hala
Mavashov, Anat
Ranen, Shahak
Brusel, Marina
Dopeso-Reyes, Iria G.
Beucher, Bertrand
Kremer, Eric J. https://orcid.org/0000-0001-6114-7530
Tolner, Else A.
Rubinstein, Moran https://orcid.org/0000-0003-2617-2276
-
Funding
Funding for this research was provided by:
Israel Science Foundation (214/22)
Dravet Syndrome Foundation (NA)
Agence Nationale de la Recherche (ANR-10-INBS-04)
EC | European Regional Development Fund (FEDER-FSE 2014-2020)
- License Information
-
More Information
Article History
Received: 10 March 2025
Accepted: 14 February 2026
First Online: 26 February 2026
Competing interests
: The authors declare no competing interests. S.F., B.B., I.G.D.R., E.J.K., and M.R. are co-inventors on a patent application covering the use of CAV2 vectors for the delivery of an SCN1A expression cassette to provide exogenous Na V 1.1 activity for the treatment of Dravet syndrome and related disorders. The patent applicant is the French National Center for Scientific Research (CNRS), Université de Montpellier, together with Ramot at Tel Aviv University Ltd., and Fundacion Para Investigacion Medica Aplicada. The patent application was filed as GB2205299.7 and published as GB2621102A, with international extension PCT/IB2023/053703), and is currently pending. In the present manuscript, CAV2-SCN1A was used as an experimental tool to assess whether exogenous SCN1A expression can correct sleep and temperature deficits in DS mice.
